8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): August 4, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Delaware                      000-28876               22-2407475
           --------                      ---------               ----------
(State or other jurisdiction of (Commission File Number) (IRS Employer
 incorporation or organization) Identification No.)


           225 Long Avenue
         Hillside, New Jersey                             07205
         --------------------                             -----
(Address of principal executive offices)                (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)






Item 5.       Other Events and Regulation FD Disclosure.

         On August 3, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release stating that the Company has selected
Irvine, CA-based Allen & Caron Inc. as its corporate communications, investor
relations, and media relations agency.  The press release is attached as an
exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No. Description
99.1        Press Release issued by Integrated BioPharma, Inc. on August 3, 2004






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  August 4, 2004             INTEGRATED BIOPHARMA, INC.


                                  By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer







                                  Exhibit Index

Exhibit No. Description
99.1        Press Release issued by Integrated BioPharma, Inc. on August 3, 2004

EX-99

NEWS RELEASE for August 3, 2004

Contact: Michael Mason (investors)          Eric Friedman, CFO
         Allen & Caron Inc                  Integrated BioPharma Inc
         212 691 8087                       973 926 0816
         michaelm@allencaron.com            e.friedman@chemintl.com


                 INTEGRATED BIOPHARMA INC SELECTS ALLEN & CARON
           FOR CORPORATE COMMUNICATIONS, INVESTOR AND MEDIA RELATIONS

HILLSIDE, NJ (August 3, 2004) - Integrated BioPharma, Inc. (Amex:INB), a
well-established biopharma company supplying active pharmaceutical ingredients,
developing new biotech products and serving the varied needs of the
nutraceutical industry, announced that it has selected Irvine, CA-based Allen &
Caron Inc as its corporate communications, investor relations and media
relations agency.

     Through its recent agreement to acquire the Hauser Contract Research
Organization, one of the world's leading experts in technologies for the
extraction, isolation, purification and synthetic modification of natural
products, INB through its wholly owned subsidiary, Paxis Pharmaceuticals, is
well-positioned to be a leading supplier of paclitaxel, the generic active
pharmaceutical ingredient (API) widely used in current cancer therapies and in
many of the next generation cancer therapies already in advanced stage clinical
trials.

     Chairman and CEO Gerald Kay said, "We have selected Allen & Caron due to
their experience and ability to assist us in properly positioning the Company
and increasing our visibility within the investment community. Allen & Caron
will help us in the dissemination of corporate information to the investment
community, as well as to industry and financial media."

     Allen & Caron Chairman and CEO Joe Allen said, "We're impressed with the
Company's business and acquisition program. We believe that our ability to
communicate its story will increase liquidity and institutional holdings of the
Company's securities."



About Allen & Caron Inc

     Allen & Caron is a full service corporate, investor and marketing
communications agency serving the needs of public companies. The Allen & Caron
international client base includes emerging growth companies in a range of
industry segments. The firm maintains offices in Irvine, CA, New York City and
London. For more information, please visit www.allencaron.com.

About Integrated BioPharma Inc (INB)

     INB serves the pharmaceutical, biotech and nutraceutical industries.
Through several wholly owned subsidiaries, INB develops, manufactures and
distributes more than 130 products worldwide. Its subsidiary, Paxis
Pharmaceuticals, Inc., develops and operates a state-of-the-art GMP facility for
the production and sale of paclitaxel and related drugs. Through its biotech
subsidiary, NuCycle Therapy, Inc., INB is developing human therapeutics and
preventive cancer compounds in transgenic plants. Further information is
available at www.iBioPharma.com.

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential risk factors that could
affect the company's financial results can be found in the company's Reports
filed with the Securities and Exchange Commission.